Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
Jean-Christophe Ianotto,
Aurélie Chauveau,
Françoise Boyer-Perrard,
Emmanuel Gyan,
Kamel Laribi,
Pascale Cony-Makhoul,
Jean-Loup Demory,
Benoit de Renzis,
Christine Dosquet,
Jerome Rey,
Lydia Roy,
Brigitte Dupriez,
Laurent Knoops,
Laurence Legros,
Mohamed Malou,
Pascal Hutin,
Dana Ranta,
Omar Benbrahim,
Valérie Ugo,
Eric Lippert,
Jean-Jacques Kiladjian
Affiliations
Jean-Christophe Ianotto
Service d’Hématologie Clinique, Institut de Cancéro-hématologie, CHRU Brest, France
Aurélie Chauveau
Laboratoire d’Hématologie, CHRU de Brest and INSERM U1078, Université de Bretagne Occidentale, Brest, France
Françoise Boyer-Perrard
Service des Maladies du Sang, CHU d’Angers, France
Emmanuel Gyan
Hématologie et Thérapie Cellulaire, CRU de Cancérologie H.S. Kaplan, Tours, France
Kamel Laribi
Service d’Hématologie, CH Le Mans, France
Pascale Cony-Makhoul
Service d’Hématologie, CH Annecy-Genevois, France
Jean-Loup Demory
Service d’Hématologie, Hôpital St Vincent de Paul, Lille, France
Benoit de Renzis
Service d’Hématologie, CHU Clermont-Ferrand, France
Christine Dosquet
APHP, Saint Louis Hospital, Cell Biology Department, Paris, France
Jerome Rey
Département d’Hématologie, Institut Paoli-Calmette, Marseille, France
Lydia Roy
Service d’Hématologie, Hôpital de Créteil, France
Brigitte Dupriez
Service d’Hématologie Clinique, CHU de Lens, France
Laurent Knoops
Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium
Laurence Legros
Service d’Hématologie, CHU de Nice, France
Mohamed Malou
Service d’Oncologie et D’Hématologie, Hôpital de Morlaix, France
Pascal Hutin
Service de Médecine Interne et de Maladies Infectieuses, Hôpital Laennec, Quimper, France
Dana Ranta
Département d’Hématologie, Hôpital Universitaire de Nancy, Vandoeuvre-lès-Nancy, France
Omar Benbrahim
Service d’Hématologie, Hôpital La Source, Orléans, France
Valérie Ugo
Laboratoire d’Hématologie, CHU d’Angers, France
Eric Lippert
Laboratoire d’Hématologie, CHRU de Brest and INSERM U1078, Université de Bretagne Occidentale, Brest, France
Jean-Jacques Kiladjian
Centre d’Investigation Clinique, Hôpital Saint-Louis, APHP, Université Paris Diderot, Inserm, Paris, France
We have previously described the safety and efficacy of pegylated interferon-α2a therapy in a cohort of 62 patients with myeloproliferative neoplasm-associated myelofibrosis followed in centers affiliated to the French Intergroup of Myeloproliferative neoplasms. In this study, we report their long-term outcomes and correlations with mutational patterns of driver and non-driver mutations analyzed by targeted next generation sequencing. The median age at diagnosis was 66 years old, the median follow-up since starting pegylated interferon was 58 months. At the time of analysis, 30 (48.4%) patients were alive including 16 still being treated with pegylated interferon. The median survival of patients with intermediate and high-risk prognostic Lille and dynamic International Prognostic Scoring System scores treated with pegylated interferon was increased in comparison to that of historical cohorts. In addition, overall survival was significantly correlated with the duration of pegylated interferon therapy (70 versus 30 months after 2 years of treatment, P
